Xifaxan Salix Pharmaceuticals, Ltd - Treatment for Travelers’ DiarrheaXifaxan is a nonsystemic gastrointestinal-selective, oral antibiotic indicated for the treatment of patients (12 years of age and older) with traveler's diarrhea caused by noninvasive strains of Escherichia coli.
Posted: May 2004
- FDA Approves Xifaxan (rifaximin) for the Treatment of IBS-D (Irritable Bowel Syndrome with Diarrhea) - May 27, 2015
- FDA Approves New Use of Xifaxan for Patients with Liver Disease - March 25, 2010
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.